Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer - Trial NCT06341296
Access comprehensive clinical trial information for NCT06341296 through Pure Global AI's free database. This Phase 2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 86 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
West China Hospital
Timeline & Enrollment
Phase 2
Apr 01, 2024
Dec 01, 2026
Primary Outcome
Objective response rate
Summary
To evaluate the objective response rate, disease control rate, progression-free survival,
 overall survival, surgical conversion rate and safety of irinotecan liposome combined with
 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer
 patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06341296
Non-Device Trial